Dr Roger Pomerantz joins Merck
This article was originally published in Scrip
Executive Summary
Merck & Co has named Dr Roger Pomerantz senior vice-president of Merck Research Laboratories and infectious diseases franchise head. He will oversee Merck's global scientific strategy across drug discovery and development for infectious diseases, including all antiviral, antibacterial, antifungal and antiparasitic agents. Dr Pomerantz has spent the past five years at Johnson & Johnson, where he most recently served as global head of infectious diseases and president of Peninsula Pharmaceuticals, a subsidiary of J&J that is focused on antibacterial research. Since 2005, he was also president of J&J's Tibotec Pharmaceuticals subsidiary, which is focused on antiviral and tuberculosis R&D.
You may also be interested in...
Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking
Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip